Atovaquone

$35$180

Products Details

Product Description

– Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and  P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].

Web ID

– HY-13832

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C22H19ClO3

References

– [1]Schöler N, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.Antimicrob Agents Chemother. 2001 Jun;45(6):1771-9.|[2]Nilsen A, et al. Quinolone-3-diarylethers: a new class of antimalarial drug.Sci Transl Med. 2013 Mar 20;5(177):177ra37.

CAS Number

– 95233-18-4

Molecular Weight

– 366.84

Compound Purity

– 99.73

SMILES

– O=C1C([C@H]2CC[C@H](C3=CC=C(Cl)C=C3)CC2)=C(O)C(C4=C1C=CC=C4)=O

Clinical Information

– Launched

Research Area

– Infection; Cancer

Solubility

– DMSO : 8.33 mg/mL (ultrasonic)

Target

– Antibiotic;Bacterial;Cytochrome P450;Parasite

Isoform

– Plasmodium

Pathway

– Anti-infection;Metabolic Enzyme/Protease

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=